Granissetrom Hikma (Granisetron)

Granissetrom Hikma is prescribed to manage nausea and vomiting in several clinical settings. It is commonly used for:

• Prevention of chemotherapy‑induced nausea and vomiting (CINV).
• Prevention of postoperative nausea and vomiting (PONV).
• Management of radiation‑induced nausea and vomiting.
• Adjunct therapy for nausea related to diagnostic procedures involving contrast agents.
• Use in patients who have not responded adequately to other antiemetic regimens.

Granisetrom Hikma may cause a range of side effects, most of which are mild to moderate in severity.

Common

• Headache
• Constipation
• Fatigue
• Dizziness
• Injection site discomfort

Serious

• Severe allergic reaction (anaphylaxis)
• Cardiac arrhythmia or QT prolongation
• Severe constipation leading to bowel obstruction
• Persistent vomiting despite therapy

Before using Granissetrom Hikma, certain precautions should be considered to ensure safe administration.

• Assess patient history for cardiac disease, especially prolonged QT interval.
• Use caution in patients with hepatic impairment, as metabolism may be reduced.
• Monitor for signs of severe constipation or bowel obstruction.
• Evaluate for hypersensitivity to granisetron or any formulation components.
• Consider dose adjustment in elderly patients.
• Avoid use in patients with known hypersensitivity to other 5‑HT3 antagonists.

Granisetrom Hikma can interact with other medications, potentially altering its efficacy or safety profile.

Avoid

• Concurrent use with other 5‑HT3 antagonists, which may increase the risk of cardiac effects.
• Co‑administration with drugs that significantly prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics).

Use with caution

• Anticholinergic agents that may exacerbate constipation.
• CYP3A4 inhibitors or inducers, which could affect granisetron metabolism.
• Medications that cause electrolyte disturbances, such as diuretics, which may predispose to cardiac arrhythmias.